The Pharma Letter4h
Erleada shows clinically-meaningful improvement in prostate cancer OS
Johnson & Johnson today released results of a landmark real-world head-to-head study showing that Erleada (apalutamide) ...
FiercePharma7h
J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...
JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer
(RTTNews) - Johnson & Johnson (JNJ), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months ...
J&J prostate cancer therapy outperforms in real-world study
Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...